⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
FBIOP News
Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
globenewswire.com
FBIO
FBIOP
Form 8-K
sec.gov
FBIOP
FBIO
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
globenewswire.com
FBIO
FBIOP